TrialAnnals of surgical oncology2023

NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.

Shishir K Maithel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.